| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in REPL over the last quarter tilts toward selling: insiders offloaded a net 79,124 shares worth roughly $1.0M.
Counted by filing, the last 12 months brought no open-market purchases and 17 sales by 7 insiders worth about $1.9M. The 12 months before that brought no open-market purchases and 10 sales by 6 insiders worth about $911K.
3 of the 17 sales in the last 12 months were made under a Rule 10b5-1 trading plan; the rest were not.
No insider has bought REPL shares in the open market in the last two years. The last purchase on record was by Jason P Rhodes on November 18, 2019.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 1.36M | $28.13M | - | |
| CEO | 708.2K | $14.62M | - | |
| Other | 224.2K | $4.63M | - | |
| CFO | 215.9K | $4.46M | - | |
| Other | 181.0K | $3.74M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Emily Luisa Hill59 | Chief Financial Officer | Sell | 9,256 | $14.28 | $132,175.68 | -4.1% | - | - | |
| Aug 10, 2026 | Andrew Schwendenman | Chief Accounting Officer | Sell | 7,632 | $12.97 | $98,987.04 | -7.1% | - | - | |
| Aug 10, 2026 | Konstantinos Xynos54 | Chief Medical Officer | Sell | 11,447 | $12.97 | $148,467.59 | -4.9% | - | - | |
| Aug 10, 2026 | Sushil Patel64 | Chief Executive Officer | Sell | 39,341 | $12.97 | $510,252.77 | -5.3% | - | - | |
| Aug 10, 2026 | Emily Luisa Hill59 | Chief Financial Officer | Sell | 11,448 | $12.97 | $148,480.56 | -4.8% | - | - | |
| Jun 1, 2026 | Christopher Sarchi55 | Chief Commercial Officer | Sell10b5-1 | 12,000 | $9.24 | $110,880.00 | -6.2% | +70.0% | - | |
| May 18, 2026 | Konstantinos Xynos54 | Chief Medical Officer | Sell | 14,023 | $5.08 | $71,236.84 | -5.6% | +192.0% | - | |
| May 18, 2026 | Andrew Schwendenman | Chief Accounting Officer | Sell | 7,894 | $5.08 | $40,101.52 | -6.9% | +192.0% | - | |
| May 18, 2026 | Christopher Sarchi55 | Chief Commercial Officer | Sell | 8,626 | $5.08 | $43,820.08 | -4.3% | +192.0% | - | |
| May 18, 2026 | Philip Astley-Sparke47 | Director | Sell | 17,657 | $5.08 | $89,697.56 | -1.2% | +192.0% | - |